• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

New Cancer Drug Satraplatin Predicted To Reach the Market in Mid 2007 for Second-Line Treatment of Patients With Hormone-Refractory Prostate Cancer

Posted on: Friday, 11 May 2007, 09:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c56643) has announced the addition of New Cancer Drug Tracker: Satraplatin to their offering.

Long gone are the days when a drug successfully completing Phase III trials was virtually assured of launch.

The results of late-stage clinical trials are scrutinised as never before, and even products that surmount safety and efficacy requirements must overcome increasingly challenging pharmacoeconomic and medical outcome hurdles.

The high cost of new cancer therapies has made them targets for critical analysis. The rewards may be great for patients and companies alike, but successfully bringing a new product to market is a complex, difficult-to-predict business.

Tracking and evaluating these new products through their late-stage development is essential and that is why both industry and the investment community will value this comprehensive new service from one of the world's leading providers of oncology business data.

Satraplatin (JM-216) GPC Biotech/Spectrum/Pharmion

Satraplatin is predicted to reach the market in mid 2007 for the second-line treatment, in combination with Prednisone, of patients with hormone-refractory prostate cancer who have failed standard chemotherapy treatment. Registrational studies are also expected in non-small cell lung and ovarian cancer, further increasing the available markets.

New Cancer Drug Tracker reports will inform you and your colleagues of the essential details of a new product's prospects and keep you up to date.

When new information is sourced by editors the two-year development tracker is updated along with any adjustment to the forecasts and estimates. Changes to the data are highlighted on the front page of the report allowing you to instantly see the latest information.

When a significant event happens the entire report is sent to you again so that the forecasts and evaluations can be reviewed in the light of the latest developments. Updates are sent for 12 months.

Content Outline:

Overview

Forecast launch date and five-year sales

- Filings and approval

- Sales forecasts and assumptions

Key evaluation criteria scoring

- Competitor Analysis Ratio Score (CARS)

- (1) Novelty/rationale for mechanism of action

- (2) Proof of concept/clinical data

- (3) Management/clinical expertise

- (4) Competition within the marketplace/gaining share of voice

- (5) Risks associated with developing a drug within a therapeutic class

Status summary for primary indications

Development timeline;

Potential competitors;

Other indications and development stages;

Development tracker;

Research methodology

For more information visit http://www.researchandmarkets.com/reports/c56643

Source: Espicom Business Intelligence

Source: Business Wire

More News in this Category